AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

TELIX PHARMACEUTICALS LTD

26.800

+0.1800.68%

Volume:1.11M

Turnover:29.80M

Market Cap:9.06B

PE:185.34

High:27.170

Open:26.880

Low:26.360

Close:26.620

Loading ...

Overview Company News Filings

Telix's Illuccix® Psma-Pet Imaging Agent Approved in Norway

THOMSON REUTERS

5 ASX 200 stocks hitting new 52-week highs today

Telix Pharmaceuticals Ltd (TLPPF) (FY 2024) Earnings Call Highlights: Record Revenue Growth and ...

Australia's Telix Pharmaceuticals jumps to record on robust forecast, results

ASX shares lifting to 52-week highs on Friday

Telix 2024 Full Year Results: Record Financial Performance and Investment in Future Growth, FY2025 Guidance of up to $1.23 Billion

THOMSON REUTERS

BRIEF-Telix Pharmaceuticals Posts FY Net Income Of AUD 49.9 Million

BRIEF-Telix Pharmaceuticals Provides FY2025 Revenue Guidance A$1.18 Bln-A$1.23 Bln

Telix Pharmaceuticals - Provides FY2025 Revenue Guidance of a$1.18 Bln to a$1.23 Bln

THOMSON REUTERS

Telix Pharmaceuticals Ltd FY Adjusted Ebitda AUD 99.3 Million

THOMSON REUTERS

Telix Pharmaceuticals Ltd FY Revenue AUD 783.2 Million

THOMSON REUTERS

Telix Pharmaceuticals Ltd FY Net Income AUD 49.9 Million

THOMSON REUTERS

Telix Pharmaceuticals-UK Mhra Approved Marketing Authorization Application for Its Prostate Cancer Pet1 Imaging Agent Illuccix

THOMSON REUTERS

Telix Says UK Regulator Approves Marketing Authorization for Prostate Imaging Product

MT Newswires Live

BRIEF-Illuccix Approved In The United Kingdom

Illuccix® Approved in the United Kingdom

THOMSON REUTERS

Telix Pharmaceuticals Ltd - Illuccix Approved in United Kingdom

THOMSON REUTERS

BRIEF-UK's MHRA Approves Gozetotide For Treatment Of Prostate Cancer

UK's Mhra: Gozetotide Approved for Treatment of Prostate Cancer - Website

THOMSON REUTERS

3 ASX growth stocks to watch as earnings hit a turning point

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/TLX.AU/news?page=7"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"TLX.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TLX.AU\",,,,,undefined,":{"symbol":"TLX.AU","market":"AU","secType":"STK","nameCN":"TELIX PHARMACEUTICALS LTD","latestPrice":26.8,"timestamp":1746771120000,"preClose":26.62,"halted":0,"volume":1111086,"delay":0,"nameEN":"TELIX PHARMACEUTICALS LTD","floatShares":274906865,"shares":337878497,"eps":0.1446,"marketStatus":"Market Closed","change":0.18,"latestTime":"05-09 16:12:00 AEST","open":26.88,"high":27.17,"low":26.36,"amount":29801371,"amplitude":0.030428,"askPrice":26.83,"askSize":8954,"bidPrice":26.76,"bidSize":1500,"shortable":3,"etf":0,"ttmEps":0.1446,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1747008000000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":26.62,"openAndCloseTimeList":[[1746748800000,1746770400000]],"volumeRatio":0.6589934372030005,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TLX.AU\",,,,,undefined,":{"symbol":"TLX.AU","floatShares":274906865,"roa":"5.33%","roe":"13.92%","lyrEps":0.150709,"volumeRatio":0.6589934372030005,"shares":337878497,"dividePrice":0,"high":27.17,"amplitude":0.030428,"preClose":26.62,"low":26.36,"week52Low":14.42,"pbRate":"15.94","psRate":"11.56","week52High":31.97,"institutionHeld":0,"latestPrice":26.8,"committee":-0.713029,"eps":0.1446,"divideRate":0,"volume":1111086,"delay":0,"ttmEps":0.1446,"open":26.88,"prevYearClose":24.61,"prevWeekClose":29.32,"prevMonthClose":27.13,"prevQuarterClose":26.52,"fiveDayClose":29.32,"twentyDayClose":24.81,"sixtyDayClose":27.75},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TLX.AU\",pageSize:20,pageCount:7,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2513904877","title":"Telix's Illuccix® Psma-Pet Imaging Agent Approved in Norway","url":"https://stock-news.laohu8.com/highlight/detail?id=2513904877","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513904877?lang=en_us&edition=fundamental","pubTime":"2025-02-24 14:00","pubTimestamp":1740376829,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250224:nTUA379DHN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TLX.AU","BK7067"],"gpt_icon":0},{"id":"2513970137","title":"5 ASX 200 stocks hitting new 52-week highs today","url":"https://stock-news.laohu8.com/highlight/detail?id=2513970137","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513970137?lang=en_us&edition=fundamental","pubTime":"2025-02-24 12:25","pubTimestamp":1740371111,"startTime":"0","endTime":"0","summary":"It's been a wild start to the trading week this Monday for ASX investors. After taking a deep plunge at market open this morning, the S&P/ASX 200 Index  and many ASX 200 stocks have since recovered. The index has currently broken even with a 0.1% rise to just over 8,300 points. As such, it might surprise you to find that we have seen a handful of ASX 200 stocks comfortably exceed that broader-market gain to mint fresh new 52-week highs today. Let's talk about those five ASX 200 stocks. Five ASX 200 stocks at new 52-week highs on Monday Here are the lucky five ASX 200 stocks that have seen new 12-month high watermarks this Monday:     ASX 200 stock  New 52-week high*  Current share price* Current gain for day*     Telstra Group Ltd   $4.21 $4.15 0.00%    Medibank Private Ltd   $4.09 $4.035 2.15%    Telix Pharmaceuticals Ltd   $30.57 $30.28 0.53%    Sims Ltd   $14.45 $14.065 0.46%    EVT Ltd    $13.65 $13.27 10.31%     *at the time of writing Why are these shares at new 52-week highs?","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/02/24/5-asx-200-stocks-hitting-new-52-week-highs-today/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7089","TLX.AU","BK7042","BK7129","MPL.AU","BK7511","TLS.AU","EVT.AU","BK7035","SGM.AU","BK7067","XJO.AU"],"gpt_icon":0},{"id":"2513266351","title":"Telix Pharmaceuticals Ltd (TLPPF) (FY 2024) Earnings Call Highlights: Record Revenue Growth and ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2513266351","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513266351?lang=en_us&edition=fundamental","pubTime":"2025-02-21 19:01","pubTimestamp":1740135675,"startTime":"0","endTime":"0","summary":"Revenue: Increased by 56% compared to the prior year.Adjusted EBITDA: Improved by 70% to $99 million.End of Year Cash Position: $710 million, bolstered by a convertible bond placement.R&D Investment: $195 million, focusing on regulatory filings and inventory scale-up.Precision Medicine Revenue Growth: 55% increase in sales of Aleix.Therapeutic Pipeline Investment: Increased by 74% to $82 million.Manufacturing Expansion: Incremental increase of $19 million in operating expenses due to acquisitions and facility expansion.2025 Revenue Guidance: Approximately $1.2 billion AUD or $770 to $800 million USD.GuruFocus has detected 8 Warning Signs with TLPPF.For the complete transcript of the earnings call, please refer to the full earnings call transcript.Telix Pharmaceuticals Ltd  reported a 56% increase in revenue, surpassing guidance.Q: How does Telix Pharmaceuticals view the market growth for US PSMA sales in 2025?","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/telix-pharmaceuticals-ltd-tlppf-fy-110115381.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["TLPPF","TLX","TLX.AU"],"gpt_icon":1},{"id":"2513287755","title":"Australia's Telix Pharmaceuticals jumps to record on robust forecast, results","url":"https://stock-news.laohu8.com/highlight/detail?id=2513287755","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513287755?lang=en_us&edition=fundamental","pubTime":"2025-02-21 11:58","pubTimestamp":1740110302,"startTime":"0","endTime":"0","summary":"UPDATE 1-Australia's Telix Pharmaceuticals jumps to record on robust forecast, resultsAdds results details in paragraph 5, CEO comment in paragraph 6 and analyst comment in paragraph 8By Aaditya Govin","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250221:nL3N3PC07U:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLX.AU","BK7067"],"gpt_icon":0},{"id":"2513247280","title":"ASX shares lifting to 52-week highs on Friday","url":"https://stock-news.laohu8.com/highlight/detail?id=2513247280","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513247280?lang=en_us&edition=fundamental","pubTime":"2025-02-21 11:18","pubTimestamp":1740107913,"startTime":"0","endTime":"0","summary":"S&P/ASX 200 Index (ASX: XJO) shares are currently down 0.17% to 8,308.9 points. Meantime, several companies are celebrating multi-year-high share prices on Friday.  Let's check them out.  ASX shares l","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/02/21/asx-shares-lifting-to-52-week-highs-on-friday/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK4079","CTD.AU","QBE.AU","BK7034","LU0708995401.HKD","BK4585","BK7503","BFL.AU","BK7104","BK4123","LU2095319765.USD","CSGP","DHG.AU","BK4548","LU0109391861.USD","TLX.AU","IE0009356076.USD","LU0672654240.SGD","ASB.AU","BK4588","BK7002","LU2210150020.SGD","BK7067","LU0390134368.USD","XJO.AU","LU1267930730.SGD","BK7135","BK7505","BK7115","LU2210149790.SGD","BK7506","LU0320765059.SGD","RMS.AU","A2M.AU","BK7070","BK7141","IE0004445239.USD"],"gpt_icon":0},{"id":"2512446089","title":"Telix 2024 Full Year Results: Record Financial Performance and Investment in Future Growth, FY2025 Guidance of up to $1.23 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=2512446089","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512446089?lang=en_us&edition=fundamental","pubTime":"2025-02-20 20:10","pubTimestamp":1740053403,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250220:nTUA1MNVS5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","TLX.AU"],"gpt_icon":0},{"id":"2512907454","title":"BRIEF-Telix Pharmaceuticals Posts FY Net Income Of AUD 49.9 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2512907454","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512907454?lang=en_us&edition=fundamental","pubTime":"2025-02-20 16:06","pubTimestamp":1740038777,"startTime":"0","endTime":"0","summary":"BRIEF-Telix Pharmaceuticals Posts FY Net Income Of AUD 49.9 Million\n\n\nFeb 20 (Reuters) - Telix Pharmaceuticals Ltd FY adjusted EBITDA AUD 99.3 million.\n\nFY revenue AUD 783.2 million\nFY net income AUD 49.9 million","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250220:nPLX7055AD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLX.AU","BK7067"],"gpt_icon":0},{"id":"2512490742","title":"BRIEF-Telix Pharmaceuticals Provides FY2025 Revenue Guidance A$1.18 Bln-A$1.23 Bln","url":"https://stock-news.laohu8.com/highlight/detail?id=2512490742","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512490742?lang=en_us&edition=fundamental","pubTime":"2025-02-20 16:06","pubTimestamp":1740038763,"startTime":"0","endTime":"0","summary":"BRIEF-Telix Pharmaceuticals Provides FY2025 Revenue Guidance A$1.18 Bln-A$1.23 BlnFeb 20 (Reuters) - Telix Pharmaceuticals Ltd TLX.AX:PROVIDES FY2025 REVENUE GUIDANCE OF A$1.18 BILLION TO A$1.23 BILLIONFurther company coverage: TLX.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250220:nFWN3PA1IZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLX.AU"],"gpt_icon":0},{"id":"2512490572","title":"Telix Pharmaceuticals - Provides FY2025 Revenue Guidance of a$1.18 Bln to a$1.23 Bln","url":"https://stock-news.laohu8.com/highlight/detail?id=2512490572","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512490572?lang=en_us&edition=fundamental","pubTime":"2025-02-20 16:01","pubTimestamp":1740038517,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250220:nFWN3PA1IZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","TLX.AU"],"gpt_icon":0},{"id":"2512905744","title":"Telix Pharmaceuticals Ltd FY Adjusted Ebitda AUD 99.3 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2512905744","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512905744?lang=en_us&edition=fundamental","pubTime":"2025-02-20 16:01","pubTimestamp":1740038486,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250220:nPLX7055AD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TLX.AU","BK7067"],"gpt_icon":0},{"id":"2512490676","title":"Telix Pharmaceuticals Ltd FY Revenue AUD 783.2 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2512490676","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512490676?lang=en_us&edition=fundamental","pubTime":"2025-02-20 16:01","pubTimestamp":1740038486,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250220:nPLX7055AD:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TLX.AU","BK7067"],"gpt_icon":0},{"id":"2512490470","title":"Telix Pharmaceuticals Ltd FY Net Income AUD 49.9 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2512490470","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512490470?lang=en_us&edition=fundamental","pubTime":"2025-02-20 16:01","pubTimestamp":1740038486,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250220:nPLX7055AD:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","TLX.AU"],"gpt_icon":0},{"id":"2511547810","title":"Telix Pharmaceuticals-UK Mhra Approved Marketing Authorization Application for Its Prostate Cancer Pet1 Imaging Agent Illuccix","url":"https://stock-news.laohu8.com/highlight/detail?id=2511547810","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511547810?lang=en_us&edition=fundamental","pubTime":"2025-02-13 21:14","pubTimestamp":1739452457,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250213:nFWN3P41FB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","TLX.AU"],"gpt_icon":0},{"id":"2511153775","title":"Telix Says UK Regulator Approves Marketing Authorization for Prostate Imaging Product","url":"https://stock-news.laohu8.com/highlight/detail?id=2511153775","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511153775?lang=en_us&edition=fundamental","pubTime":"2025-02-13 08:10","pubTimestamp":1739405411,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals  said that the UK Medicines and Healthcare Products Regulatory Agency  granted marketing authorization for its prostate cancer imaging agent, Illuccix, according to a Thursday filing with the Australian bourse.The approval allows for the detection and localization of prostate-specific membrane antigen-positive lesions in adults with prostate cancer through positron emission tomography imaging, the filing said.Illuccix will be distributed in the UK through Telix's partner, Xiel, a distributor of nuclear medicine, radiotherapy, and diagnostic radiology technologies.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TLX.AU","BK7067"],"gpt_icon":1},{"id":"2511625539","title":"BRIEF-Illuccix Approved In The United Kingdom","url":"https://stock-news.laohu8.com/highlight/detail?id=2511625539","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511625539?lang=en_us&edition=fundamental","pubTime":"2025-02-13 06:42","pubTimestamp":1739400132,"startTime":"0","endTime":"0","summary":"BRIEF-Illuccix Approved In The United KingdomFeb 12 (Reuters) - Telix Pharmaceuticals Ltd TLX.AX:ILLUCCIX® APPROVED IN THE UNITED KINGDOMSource text: ID:nGNX2cjTDnFurther company coverage: TLX.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250212:nFWN3P31T6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLX.AU","BK7067"],"gpt_icon":0},{"id":"2511538035","title":"Illuccix® Approved in the United Kingdom","url":"https://stock-news.laohu8.com/highlight/detail?id=2511538035","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511538035?lang=en_us&edition=fundamental","pubTime":"2025-02-13 05:38","pubTimestamp":1739396294,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250212:nFWN3P31T6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","TLX.AU"],"gpt_icon":0},{"id":"2511558449","title":"Telix Pharmaceuticals Ltd - Illuccix Approved in United Kingdom","url":"https://stock-news.laohu8.com/highlight/detail?id=2511558449","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511558449?lang=en_us&edition=fundamental","pubTime":"2025-02-13 04:19","pubTimestamp":1739391592,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250212:nFWN3P31SL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","TLX.AU"],"gpt_icon":0},{"id":"2511304737","title":"BRIEF-UK's MHRA Approves Gozetotide For Treatment Of Prostate Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2511304737","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511304737?lang=en_us&edition=fundamental","pubTime":"2025-02-13 00:35","pubTimestamp":1739378104,"startTime":"0","endTime":"0","summary":"BRIEF-UK's MHRA Approves Gozetotide For Treatment Of Prostate CancerFeb 12 (Reuters) - UK's MHRA:UK'S MHRA: GOZETOTIDE APPROVED FOR TREATMENT OF PROSTATE CANCER - WEBSITEFurther company coverage: TLX.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250212:nFWN3P31SC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLX.AU","BK7067"],"gpt_icon":0},{"id":"2511304445","title":"UK's Mhra: Gozetotide Approved for Treatment of Prostate Cancer - Website","url":"https://stock-news.laohu8.com/highlight/detail?id=2511304445","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511304445?lang=en_us&edition=fundamental","pubTime":"2025-02-13 00:33","pubTimestamp":1739378028,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250212:nFWN3P31SC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TLX.AU","BK7067"],"gpt_icon":0},{"id":"2510534586","title":"3 ASX growth stocks to watch as earnings hit a turning point","url":"https://stock-news.laohu8.com/highlight/detail?id=2510534586","media":"LiveWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510534586?lang=en_us&edition=fundamental","pubTime":"2025-02-12 14:02","pubTimestamp":1739340159,"startTime":"0","endTime":"0","summary":"This interview was recorded on Tuesday 11 February 2025.Share markets are at near-highs. The RBA is expected to start cuts next week. There’s change in the air and something that seems like…hope. FNArena’s Rudi Filapek-Vandycknotes that all reporting seasons have their own character and this one spells a significant change compared to the more depressed mood of August 2024. The optimism is back and Filapek-Vandyck points to a few key reasons.“There is a growing confidence now that earnings in Australia have bottomed, and we will see better times ahead. That’s already being reflected in forecasts,” he says.He adds that the prospect of rate cuts supports his optimism and his view that 2025 may be the year that the “60% that haven’t performed over the past two years” finally get going.The two sectors and three stocks to watch this season. “The one telecommunication company that has been put forward as potentially shooting out the lights this year is Superloop and they have been on a tear ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/3-asx-growth-stocks-to-watch-as-earnings-hit-a-turning-point","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/3-asx-growth-stocks-to-watch-as-earnings-hit-a-turning-point","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"livewire_stock","symbols":["BK7509","TPG.AU","XAO.AU","BK7067","XKO.AU","BK7124","MQG.AU","HLS.AU","ACL.AU","SHL.AU","TLS.AU","BK7054","BK7113","TLX.AU","BK7015","COH.AU","BK7501","BK7094","BK7016","PME.AU","XJO.AU","BK7007","HUB.AU","INTEU","RMD.AU","WTC.AU","BK7046","BK7511","BK7135","SLC.AU","BK7508","CBA.AU","BK7503","BK7042","RHC.AU","CSL.AU","IDX.AU"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":7,"totalSize":200,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TLX.AU\",params:#limit:5,,,undefined,":[{"date":"2025-02-19","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1739919600000,"name":null,"time":"","dateTimestamp":1739883600000,"actualEps":null},{"date":"2024-08-22","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1724284800000,"name":null,"time":"","dateTimestamp":1724248800000,"actualEps":null},{"date":"2024-02-22","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1708556400000,"name":null,"time":"","dateTimestamp":1708520400000,"actualEps":null},{"date":"2023-10-18","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1697583600000,"name":null,"time":"","dateTimestamp":1697547600000,"actualEps":null},{"date":"2023-08-23","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1692748800000,"name":null,"time":"","dateTimestamp":1692712800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TLX.AU\",market:\"AU\",,,undefined,":[]}}